What we're tracking right now.
Recent WeighedHealth coverage: FDA decisions, recalls, GLP-1 shortage updates, legislation tracking, and editorial deep-dives.
Trackers
Recall & safety coverage
All recalls →ProRx LLC recalls compounded semaglutide and tirzepatide (October 2025)
In October 2025, compounder ProRx LLC initiated a voluntary nationwide recall of lots of its compounded semaglutide and tirzepatide injectable products due to lack of sterility assurance identified during inspection. Recalled lots and distribution details are listed in the FDA Enforcement Report database. Non-sterile injectables carry a risk of injection-site and bloodstream infections. Patients with affected lots were instructed to stop use and contact their dispensing pharmacy; no confirmed patient harm had been reported at announcement.
FDA warning letters to GLP-1 compounders and sellers, September 2025
With the tirzepatide shortage declared resolved in December 2024 and the semaglutide shortage in February 2025, the legal basis for routinely compounding "essentially a copy" of those drugs ended. In September 2025 the FDA announced a wave of warning letters to companies that continued compounding GLP-1 products or marketing unapproved GLP-1 drugs — citing violations of compounding rules, sourcing of semaglutide salt forms not permitted for compounding, and misleading marketing claims about equivalence to the approved products. Many recipients discontinued GLP-1 compounding; enforcement against non-compliant sellers has continued into 2026. Individual letters are published in the FDA's warning-letters database.
FDA declares semaglutide injection shortage resolved (February 2025)
On February 21, 2025 the FDA announced its determination that the shortage of semaglutide injection products (Wegovy and Ozempic) was resolved, with Novo Nordisk able to meet current and projected US demand. Because compounding of "essentially a copy" of an FDA-approved drug is only permitted during a shortage, the determination started a wind-down period for compounded semaglutide: 503A compounding pharmacies were given until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop producing it. Telehealth services that had offered compounded semaglutide during the shortage transitioned patients to branded Wegovy/Ozempic or alternative therapies.
FDA alert: counterfeit Ozempic pens found in US supply chain
On December 21, 2023 the FDA alerted patients, pharmacies, and wholesalers that counterfeit Ozempic (semaglutide) 1 mg pens had entered the US drug-supply chain outside authorized channels. The counterfeit products carry lot number NAR0074 with serial number 430834149057. FDA and Novo Nordisk seized thousands of units and advised that the pen needles in the counterfeit kits are themselves counterfeit, so their sterility cannot be assured. FDA reported a small number of adverse-event reports associated with the lot, none serious and consistent with known GI side effects of semaglutide. Wholesalers, pharmacies, and patients were told not to distribute, dispense, or use pens labeled with that lot/serial combination.
Latest articles
All articles →- glp1
How much weight do you actually lose on a GLP-1? The trial numbers
Not the marketing numbers or the before-and-after photos, but the figures from the registration trials that got these drugs approved. What STEP 1 and SURMOUNT-1 actually showed, the cardiovascular signal from SELECT, and three things the numbers do not say.
- glp1
Does insurance cover GLP-1s for weight loss? A 2026 reality check
The honest answer is 'it depends', but it depends on a small number of things you can actually check. The decision tree: diabetes vs. weight loss, prior authorization, how Medicare and Medicaid differ, the ten-minute coverage check, and what to do if you are denied.
- glp1
Is compounded semaglutide still legal in 2026? A plain-English answer
The short version: sometimes, for specific medical reasons, but 'because it's cheaper' is no longer one of them. What changed when the FDA shortage ended, whether you can still get compounded GLP-1, and the questions that separate a legitimate program from a risky one.
- glp1
What a GLP-1 program actually costs in 2026, and the one number nobody advertises
The sticker price you see is almost never the price you pay. Here is how to read a GLP-1 telehealth quote (platform fee, medication, and labs) before you hand over a card, and why the all-in monthly cost is the only figure that matters.
- skincare
Melasma Treatment: What Actually Works in 2026
Melasma is chronic and sun-driven, so no cream fixes it for good. Here is the evidence-based core — tinted sunscreen, hydroquinone, the triple-combination cream, azelaic acid, and when procedures help or backfire.
- skincare
How to Get Rid of Dark Spots and Hyperpigmentation: An Evidence-Based Guide (2026)
Dark spots are excess melanin left behind by acne, injury, or sun. Here is what actually fades them, ranked by evidence, with realistic timelines and when to see a dermatologist.
- skincare
Azelaic Acid for Acne, Rosacea, and Pigmentation: What It Does and Who It's For
Azelaic acid fights acne bacteria, calms rosacea redness, and fades dark spots by blocking tyrosinase. Here is how the 10% OTC, 15% gel, and 20% cream differ, what it treats, side effects, and why it is a common pregnancy-friendly pick.
- skincare
Niacinamide Benefits for Skin: What the Evidence Actually Shows
Topical niacinamide (vitamin B3) has solid evidence for barrier support, less facial oil, and modest fading of dark spots and redness at 2 to 5%. Here is what it really does, what it does not, and how to layer it with retinoids and vitamin C.
- mental_health
Escitalopram (Generic Lexapro): What It Is and How It's Used
Escitalopram is the generic of Lexapro, an SSRI approved for depression and anxiety. How it works, dosing, onset, side effects, the under-25 boxed warning, and safe stopping.
- mental_health
Bupropion (Wellbutrin): What to Know in 2026
Bupropion is an atypical antidepressant that works on norepinephrine and dopamine instead of serotonin. Here is its distinctive profile versus SSRIs, plus the seizure risk and safety cautions that shape how it is prescribed.
- mental_health
Propranolol for Performance Anxiety: What It Does and Doesn't Do (2026)
Propranolol is a beta-blocker used off-label for stage fright and performance nerves. It blunts the physical adrenaline symptoms like racing heart and shaky hands, but it does not treat the worry itself or chronic anxiety, and it carries real heart and lung contraindications.
- daily_health
Magnesium for Sleep: Does It Actually Work? A 2026 Evidence Review
An honest evidence review of magnesium for sleep: the trials are small and low-quality, the benefit is modest and limited to older adults, and it works best only if your intake is low.
Press inquiries: [email protected] · Press kit · RSS feed